Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.05, MarketWatch Earnings reports. The business had revenue of $37.30 million for the quarter, compared to the consensus estimate of $37.17 million. Agios Pharmaceuticals had a negative return on equity of 59.38% and a negative net margin of 182.49%. Agios Pharmaceuticals’s revenue was up 42.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.87) EPS.

AGIO opened at $45.32 on Friday. The company has a fifty day moving average price of $51.61 and a two-hundred day moving average price of $47.27. The firm has a market capitalization of $3.12 billion, a PE ratio of -8.53 and a beta of 2.14. Agios Pharmaceuticals has a 52 week low of $27.77 and a 52 week high of $56.74. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.27 and a current ratio of 8.41.

In other news, insider Christopher Bowden sold 3,583 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $50.01, for a total value of $179,185.83. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.16% of the company’s stock.

Several equities analysts have issued reports on the company. Needham & Company LLC began coverage on Agios Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $71.00 price objective for the company. Piper Sandler lifted their price target on Agios Pharmaceuticals from $70.00 to $80.00 and gave the company an “overweight” rating in a report on Friday, June 12th. JPMorgan Chase & Co. increased their price objective on shares of Agios Pharmaceuticals from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Guggenheim raised their price objective on shares of Agios Pharmaceuticals from $60.00 to $66.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Finally, Citigroup upped their target price on shares of Agios Pharmaceuticals from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $68.77.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Story: Straddles

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.